: SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.

SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.

The bnt162b2 vaccine induces humoral and cellular immune memory to sars-cov-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age / Cinicola, Bianca Laura; Piano Mortari, E; Zicari, Anna Maria; Agrati, Chiara; Bordoni, Veronica; Albano, Christian; Fedele, Giorgio; Schiavoni, Ilaria; Leone, Pasqualina; Fiore, Stefano; Capponi, Martina; Conti, Maria Giulia; Petrarca, Laura; Stefanelli, Paola; Spalice, Alberto; Midulla, Fabio; Palamara, Anna Teresa; Quinti, Isabella; Locatelli, Franco; Carsetti, Rita. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022), pp. 1-11. [10.3389/fimmu.2022.1094727]

The bnt162b2 vaccine induces humoral and cellular immune memory to sars-cov-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age

Cinicola, Bianca Laura;Piano Mortari, E;Zicari, Anna Maria;Bordoni, Veronica;Fedele, Giorgio;Capponi, Martina;Conti, Maria Giulia;Petrarca, Laura;Spalice, Alberto;Midulla, Fabio;Palamara, Anna Teresa;Quinti, Isabella;
2022

Abstract

SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.
2022
: SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.
omicron; sars-cov-2; antibodies; antigen-specific t cells; children; immune memory; memory b cells; vaccine
01 Pubblicazione su rivista::01a Articolo in rivista
The bnt162b2 vaccine induces humoral and cellular immune memory to sars-cov-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age / Cinicola, Bianca Laura; Piano Mortari, E; Zicari, Anna Maria; Agrati, Chiara; Bordoni, Veronica; Albano, Christian; Fedele, Giorgio; Schiavoni, Ilaria; Leone, Pasqualina; Fiore, Stefano; Capponi, Martina; Conti, Maria Giulia; Petrarca, Laura; Stefanelli, Paola; Spalice, Alberto; Midulla, Fabio; Palamara, Anna Teresa; Quinti, Isabella; Locatelli, Franco; Carsetti, Rita. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022), pp. 1-11. [10.3389/fimmu.2022.1094727]
File allegati a questo prodotto
File Dimensione Formato  
Cinicola_Vaccine-induces-humoral_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.3 MB
Formato Adobe PDF
3.3 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1679033
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact